Status: Pending
Age: New (14/08/2025)
ICICI Securities Recommends Buy on Akums Drugs and Pharmaceuticals with Target of ₹655
Brokerage
ICICI Securities
Analyst
Brokerage Team
Position
Bullish
Start Date
14/08/2025
Horizon
Mid Term
Target Price and Expected Returns
Start Price
Target Price
₹655
Expected Returns
Summary
ICICI Securities is bullish on Akums Drugs and Pharmaceuticals, recommending a buy rating with a target price of ₹655.
ICICI Securities's justification for Akums Drugs and Pharmaceuticals target price prediction
- Revenue moderated across verticals but gross margin expanded.
- CDMO segment growth slowed but API losses are narrowing.
- Management revised guidance to mid-single-digit growth for CDMO segment.
- API losses expected to shrink by INR 200mn in FY26.
- Cash balance of INR 15.2bn may be used for M&A to improve scale.
Sources:
https://www.whatsapp.com/channel/0029Va2JvT3LtOj3x6oZcO1D
Tags: